Celsion Corporation (CLSN)

[Tulaz1]

Celsion Affirms July Timing for Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer


We believe that a successful study has blockbuster revenue potential and, more importantly, will be globally transformational for patients with HCC, the largest unmet need in oncology with more than 750,000 cases annually.”


https://www.globenewswire.com/news-release/2020/06/25/2053369/0/en/Celsion-Affirms-July-Timing-for-Second-Interim-Analysis-of-the-Phase-III-OPTIMA-Study-of-ThermoDox-in-Primary-Liver-Cancer.html